Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of CTX.WA is 106 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell